These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17404170)

  • 1. Cytomegalovirus infection and cardiac allograft vasculopathy in children.
    Webber SA
    Circulation; 2007 Apr; 115(13):1701-2. PubMed ID: 17404170
    [No Abstract]   [Full Text] [Related]  

  • 2. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.
    Hussain T; Burch M; Fenton MJ; Whitmore PM; Rees P; Elliott M; Aurora P
    Circulation; 2007 Apr; 115(13):1798-805. PubMed ID: 17353448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy.
    Everett JP; Hershberger RE; Norman DJ; Chou S; Ratkovec RM; Cobanoglu A; Ott GY; Hosenpud JD
    J Heart Lung Transplant; 1992; 11(3 Pt 2):S133-7. PubMed ID: 1320405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of cytomegalovirus infection, confirmed by pp65 antigen presence, on the development of cardiac allograft vasculopathy.
    Zakliczyński M; Krynicka-Mazurek A; Pyka Ł; Trybunia D; Nadziakiewicz P; Przybylski R; Zembala M
    Transplant Proc; 2007 Nov; 39(9):2866-9. PubMed ID: 18022004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract]   [Full Text] [Related]  

  • 7. Direct and indirect effects of cytomegalovirus: can we prevent them?
    Razonable R
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):1-5. PubMed ID: 20022410
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of cytomegalovirus in cardiac allograft vasculopathy.
    Weill D
    Transpl Infect Dis; 2001; 3 Suppl 2():44-8. PubMed ID: 11926750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of epidemiology and treatment factors to infection and allograft survival in renal transplantation.
    Betts RF
    Birth Defects Orig Artic Ser; 1984; 20(1):87-99. PubMed ID: 6329375
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute rejection and cytomegalovirus infection: correlation with cardiac allograft vasculopathy.
    Mangiavacchi M; Frigerio M; Gronda E; Danzi GB; Bonacina E; Masciocco G; Olivia F; De Vita C; Pellegrini A
    Transplant Proc; 1995 Jun; 27(3):1960-2. PubMed ID: 7792851
    [No Abstract]   [Full Text] [Related]  

  • 11. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'.
    Rubin RH
    Curr Opin Infect Dis; 2007 Aug; 20(4):399-407. PubMed ID: 17609600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of cytomegalovirus prophylaxis in solid organ transplantation.
    Pescovitz MD
    Transplantation; 2006 Jul; 82(2 Suppl):S4-8. PubMed ID: 16858270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection after liver transplantation.
    Chen YS; Chen CL; Kuo YC; Sun CK
    Transplant Proc; 1994 Aug; 26(4):2229-30. PubMed ID: 8066728
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiviral antibodies in transplantation.
    Snydman DR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):10-2. PubMed ID: 7482809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study.
    Moreno de la Higuera Díaz MA; Calvo Romero N; Sánchez-Fructuoso A; Conesa J; Marques Vidas M; Prats D; Barrientos Guzmán A
    Transplant Proc; 2007 Sep; 39(7):2231-2. PubMed ID: 17889147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus-associated allograft rejection in heart transplant patients.
    Potena L; Valantine HA
    Curr Opin Infect Dis; 2007 Aug; 20(4):425-31. PubMed ID: 17609604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic cytomegalovirus management strategies.
    Martin M
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):23-7. PubMed ID: 7482812
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection.
    Rand KH; Pollard RB; Merigan TC
    N Engl J Med; 1978 Apr; 298(17):951-3. PubMed ID: 205784
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of cytomegalovirus antibody status on graft survival in renal transplantation.
    Fauchald P; Leivestad T; Rollag H; Albrechtsen D; Sødal G
    Transplant Proc; 1994 Jun; 26(3):1725. PubMed ID: 8030103
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytomegalovirus infection in pediatric heart transplantation.
    Fukushima N; Gundry SR; Razzouk AJ; Bailey LL
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1423-5. PubMed ID: 8382868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.